ProMIS Neurosciences Reports First Human Data for Alzheimer's Drug PMN310

ProMIS Neurosciences Inc. (Nasdaq: PMN) has announced positive human data from its Phase 1a clinical trials for PMN310, its lead drug candidate for Alzheimer's disease. The company presented the first human evidence that the drug demonstrated a dose-dependent reduction of toxic amyloid-beta oligomers (AβO) in the cerebrospinal fluid (CSF) of healthy volunteers following a single dose. These significant findings were shared at the 2026 Alzheimer's Association International Conference (AAIC) and represent one of the first quantitative measures of PMN310's engagement with its intended targets.

PMN310 is a humanized IgG1 monoclonal antibody designed to selectively target only the toxic amyloid-beta oligomers, believed to be among the earliest and most damaging drivers of Alzheimer's disease. This selectivity may reduce the risk of amyloid-related imaging abnormalities (ARIA), which are commonly associated with other plaque-binding antibodies. In the Phase 1a trial, PMN310 was generally well-tolerated, with no treatment-related serious adverse events reported.

According to the trial data, PMN310 administration resulted in a dose-dependent reduction in detectable AβO levels in CSF. While healthy individuals carry lower oligomer burdens than Alzheimer's patients, amyloid-beta oligomers are detectable in CSF even in cognitively normal adults, making this a meaningful measure of target engagement. Neil Warma, Chief Executive Officer of ProMIS Neurosciences, stated that these data represent an important milestone for PMN310 and support their precision medicine approach in treating Alzheimer's disease.

These encouraging results for PMN310, which received Fast Track Designation from the U.S. Food and Drug Administration (FDA) in July 2025, are being closely watched by the markets. The company's stock experienced positive investor interest following the announcement. Analysts suggest that PMN310's differentiated mechanism of action and potentially cleaner side effect profile could position the drug uniquely in both clinical development and the market.

Following these promising Phase 1a results, ProMIS Neurosciences initiated the PRECISE-AD Phase 1b trial to evaluate PMN310 in patients with mild cognitive impairment due to AD or mild AD. This trial, which has fully enrolled 144 participants, is on track to present six-month blinded interim data in the coming weeks (expected early Q3 2026). Top-line unblinded results from the full trial are anticipated in early Q1 2027.

These developments underscore the importance of new approaches in Alzheimer's disease treatment. The potential of such drugs to slow or halt disease progression offers significant hope for patients and global healthcare systems alike. Analysts anticipate that with these data, ProMIS Neurosciences could establish a strong position in the competitive Alzheimer's landscape, with future Phase 1b data being crucial for the company's market valuation.